• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Rezolute Inc. (Amendment)

    2/14/23 1:27:03 PM ET
    $RZLT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $RZLT alert in real time by email
    SC 13G/A 1 d9939533_13g-a.htm

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 2)*

     

     

    Rezolute, Inc.
    (Name of Issuer)

     

     

    Common Stock, $0.001 par value per share
    (Title of Class of Securities)

     

     

    76200L309
    (CUSIP Number)

     

     

    December 31, 2022
    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    [_] Rule 13d-1(b)

     

    [X] Rule 13d-1(c)

     

    [_] Rule 13d-1(d)

     

    __________

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     
     

     

    CUSIP No 76200L309    

     

         
    1. NAME OF REPORTING PERSONS  
         
      Caxton Corporation  
         
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
        (a)  [_]
        (b)  [X]
         
    3. SEC USE ONLY  
         
         
         
    4. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      Delaware  
         
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
         
    5. SOLE VOTING POWER  
         
      0  
         
    6. SHARED VOTING POWER  
         
      1,860,518  
         
    7. SOLE DISPOSITIVE POWER  
         
      0  
         
    8. SHARED DISPOSITIVE POWER  
         
      1,860,518  
         
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
         
      1,860,518  
         
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)  
        [_]
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
         
      4.99%  
         
    12.

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    CO

     

     

     
     

     

     

     

    CUSIP No 76200L309    

     

         
    1. NAME OF REPORTING PERSONS  
         
      CDK Associates, L.L.C.  
         
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
        (a)  [_]
        (b)  [X]
         
    3. SEC USE ONLY  
         
         
         
    4. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      Delaware  
         
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
         
    5. SOLE VOTING POWER  
         
      0  
         
    6. SHARED VOTING POWER  
         
      1,860,518  
         
    7. SOLE DISPOSITIVE POWER  
         
      0  
         
    8. SHARED DISPOSITIVE POWER  
         
      1,860,518  
         
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
         
      1,860,518  
         
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)  
        [_]
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
         
      4.99%  
         
    12.

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    OO

     

     

     
     

     

     

     

     

    CUSIP No 76200L309    

     

         
    1. NAME OF REPORTING PERSONS  
         
      Bruce S. Kovner  
         
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
        (a)  [_]
        (b)  [X]
         
    3. SEC USE ONLY  
         
         
         
    4. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      United States  
         
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
         
    5. SOLE VOTING POWER  
         
      0  
         
    6. SHARED VOTING POWER  
         
      1,860,518  
         
    7. SOLE DISPOSITIVE POWER  
         
      0  
         
    8. SHARED DISPOSITIVE POWER  
         
      1,860,518  
         
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
         
      1,860,518  
         
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)  
        [_]
         
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
         
      4.99%  
         
    12.

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

    IN

     

     

     
     

     

     

     



    CUSIP No
    76200L309    

     

    Item 1. (a). Name of Issuer:  
           
        Rezolute, Inc.  

     

      (b). Address of Issuer's Principal Executive Offices:  
           
       

    275 Shoreline Drive, Suite 500

    Redwood City, California 94065

     

     

    Item 2. (a). Name of Person Filing:  
           
       

    Caxton Corporation

    CDK Associates, L.L.C.

    Bruce S. Kovner

     

     

      (b). Address of Principal Business Office, or if None, Residence:  
           
       

    Caxton Corporation

    731 Alexander Road,

    Building 2, Suite 500

    Princeton, New Jersey 08540

     

    CDK Associates, L.L.C.

    c/o Caxton Corporation

    731 Alexander Road,

    Building 2, Suite 500

    Princeton, New Jersey 08540

     

    Bruce S. Kovner

    c/o Caxton Corporation

    731 Alexander Road,

    Building 2, Suite 500

    Princeton, New Jersey 08540

     

     

      (c). Citizenship:  
           
       

    Caxton Corporation – Delaware corporation

    CDK Associates, L.L.C. – Delaware limited liability company

    Bruce S. Kovner – United States citizen

     

     

      (d). Title of Class of Securities:  
           
        Common Stock, $0.001 par value per share  

     

      (e). CUSIP Number:  
           
        76200L309  
     
     

     


    Item 3.
    If This Statement is filed pursuant to ss.240.13d-1(b) or 240.13d-2(b), or (c), check whether the person filing is a

     

      (a) [_] Broker or dealer registered under Section 15 of the Exchange Act (15 U.S.C. 78c).
           
      (b) [_] Bank as defined in Section 3(a)(6) of the Exchange Act (15 U.S.C. 78c).
           
      (c) [_] Insurance company as defined in Section 3(a)(19) of the Exchange Act (15 U.S.C. 78c).
           
      (d) [_] Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
           
      (e) [_] An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
           
      (f) [_] An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
           
      (g) [_] A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);
           
      (h) [_] A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C.1813);
           
      (i) [_] A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
           
      (j)   [_] Group, in accordance with s.240.13d-1(b)(1)(ii)(J).

     

     
     

     

    Item 4. Ownership.

     

      Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

      (a)   Amount beneficially owned:
         
       

    1,860,518 shares deemed beneficially owned by Caxton Corporation

    1,860,518 shares deemed beneficially owned by CDK Associates, L.L.C.

    1,860,518 shares deemed beneficially owned by Bruce S. Kovner

     

      (b)   Percent of class:
         
       

    4.99% deemed beneficially owned by Caxton Corporation

    4.99% deemed beneficially owned by CDK Associates, L.L.C.

    4.99% deemed beneficially owned by Bruce S. Kovner

     

      (c)   Number of shares as to which Caxton Corporation has:

     

      (i) Sole power to vote or to direct the vote 0 ,
           
      (ii) Shared power to vote or to direct the vote 1,860,518 ,
           
      (iii) Sole power to dispose or to direct the disposition of 0 ,
           
      (iv) Shared power to dispose or to direct the disposition of 1,860,518 .

     

      Number of shares as to which CDK Associates, L.L.C. has:

     

      (i) Sole power to vote or to direct the vote 0 ,
           
      (ii) Shared power to vote or to direct the vote 1,860,518 ,
           
      (iii) Sole power to dispose or to direct the disposition of 0 ,
           
      (iv) Shared power to dispose or to direct the disposition of 1,860,518 .

     

      Number of shares as to which Bruce S. Kovner has:

     

      (i) Sole power to vote or to direct the vote 0 ,
           
      (ii) Shared power to vote or to direct the vote 1,860,518 ,
           
      (iii) Sole power to dispose or to direct the disposition of 0 ,
           
      (iv) Shared power to dispose or to direct the disposition of 1,860,518 .

     

    Item 5. Ownership of Five Percent or Less of a Class.
       
      If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [X].
       
       
       

     

     
     

     

    Item 6. Ownership of More Than Five Percent on Behalf of Another Person.
       
      If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than five percent of the class, such person should be identified.  A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.
       
      The shares of the Issuer reported herein are held in the accounts of CDK Associates, L.L.C., and another entity for which Caxton Corporation is deemed to have beneficial ownership.  Bruce S. Kovner is the Chairman and sole shareholder of Caxton Corporation.  
       
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.
       
      If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(1)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary.  If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.
       
      N/A
       
    Item 8. Identification and Classification of Members of the Group.
       
      If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group.  If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group.
       
      N/A
       
    Item 9. Notice of Dissolution of Group.
       
      Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity.  See Item 5.
       
      N/A
       
    Item 10. Certification.
       
      By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

     

     

     
     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

      Caxton Corporation*
         
       
      By: /s/ Heath N. Weisberg
      Name: Heath N. Weisberg
      Title: General Counsel and Chief Compliance Officer
         
      CDK Associates, L.L.C.*
         
      By:  Caxton Corporation, its manager
       
      By: /s/ Heath N. Weisberg
      Name: Heath N. Weisberg
      Title: General Counsel and Chief Compliance Officer
         
      BRUCE S. KOVNER*
         
       
      By: /s/ Heath N. Weisberg
      Name: Heath N. Weisberg
      Title: Attorney-in-Fact for Bruce S. Kovner
         
      February 14, 2023

     

     

    * The Reporting Persons disclaim beneficial ownership in the Shares reported herein except to the extent of their pecuniary interest therein.

    The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representative's authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

    Note. Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See s.240.13d-7 for other parties for whom copies are to be sent.

    Attention. Intentional misstatements or omissions of fact constitute Federal criminal violations (see 18 U.S.C. 1001).

     
     

    Exhibit A

    AGREEMENT

    The undersigned agree that this Schedule 13G Amendment dated February 14, 2023 relating to the Common Stock, $0.001 par value per share of Rezolute, Inc., shall be filed on behalf of the undersigned.

      Caxton Corporation
         
       
      By: /s/ Heath N. Weisberg
      Name: Heath N. Weisberg
      Title: General Counsel and Chief Compliance Officer
         
         
      CDK Associates, L.L.C.
         
      By:  Caxton Corporation, its manager
       
      By: /s/ Heath N. Weisberg
      Name: Heath N. Weisberg
      Title: General Counsel and Chief Compliance Officer
         
         
      BRUCE S. KOVNER
         
       
      By: /s/ Heath N. Weisberg
      Name: Heath N. Weisberg
      Title: Attorney-in-Fact for Bruce S. Kovner
         
      February 14, 2023

     

     

     

     

     
     

    Exhibit B

     

    POWER OF ATTORNEY

     

    Know all by these presents, that the undersigned hereby constitutes and appoints Heath Weisberg, signing singly, with full power of substitution, the undersigned’s true and lawful attorney-in-fact to:

     

    (1) execute for and on behalf of the undersigned any applications, reports, or documents required or deemed appropriate by the attorney-in-fact to file pursuant to (i) the United States Securities Exchange Act of 1934, as amended, or any rule, or regulation thereunder, including, without limitation, Schedules 13D, 13G, 13F, and 13H, and Forms 3, 4, and 5, (ii) the Securities Act of 1933, as amended, or any rule or regulation thereunder, including, without limitation, Form 144, (iii) the U.S. Commodity Exchange Act, as amended or any rule or regulation thereunder, or (iv) the statutes, rules or regulations of any other domestic or foreign governmental or self-regulatory authority;

     

    (2) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such applications, reports, or documents;

     

    (3) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interests of, or legally required by the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact’s discretion.

     

    The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact’s substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorney-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned’s responsibilities to comply with the applicable statutes, rules and regulations.

     

    This Power of Attorney shall remain in full force and effect until revoked by the undersigned in a signed writing delivered to the foregoing attorney-in-fact or otherwise terminated by my death or other event described in section 5-1511 of the New York General Obligations Law.

     

    SIGNATURE AND ACKNOWLEDGMENT:

     

    In Witness Whereof I have hereunto signed my name on the 9th day of May, 2013.

     

    /s/ Bruce Kovner

    Bruce Kovner

     

     
     

     

     

    STATE OF NEW YORK )  
      ) ss:  
    COUNTY OF NEW YORK )  

     

    On the 9th day of May 2013, before me, the undersigned, personally appeared Bruce Kovner, personally known to me or proved to me on the basis of satisfactory evidence to be the individual whose name is subscribed to the within instrument and acknowledged to me that he/she executed the same in his/her capacity, and that by his/her signature on the instrument, the individual, or the person upon behalf of which the individual acted, executed the instrument.

     

     

    /s/ Cynthia Rosel Rivera

    Notary Public

     

     

    AGENT’S SIGNATURE AND ACKNOWLEDGMENT OF APPOINTMENT:

     

    I, Heath N. Weisberg, have read the foregoing Power of Attorney. I am the person identified therein as agent and attorney-in-fact for the principal named therein.

     

    I acknowledge my legal responsibilities.

     

    /s/ Heath N. Weisberg

    Heath N. Weisberg

     

    STATE OF NEW YORK )  
      ) ss:  
    COUNTY OF NEW YORK )  

     

    On the 9th day of May, 2013, before me, the undersigned, personally appeared Heath N. Weisberg, personally known to me or proved to me on the basis of satisfactory evidence to be the individual whose name is subscribed to the within instrument and acknowledged to me that he/she executed the same in his/her capacity, and that by his/her signature on the instrument, the individual, or the person upon behalf of which the individual acted, executed the instrument.

     

     

     

    /s/ Cynthia Rosel Rivera

    Notary Public

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Get the next $RZLT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $RZLT

    DatePrice TargetRatingAnalyst
    12/11/2025$2.00Buy → Hold
    Craig Hallum
    12/11/2025Overweight → Neutral
    Cantor Fitzgerald
    12/11/2025$1.00Outperform → Neutral
    Wedbush
    11/5/2024$12.00Outperform
    Wedbush
    8/27/2024$11.00Buy
    Guggenheim
    7/17/2024$13.00Buy
    BTIG Research
    6/4/2024$14.00Buy
    Craig Hallum
    4/9/2024$8.00Buy
    Maxim Group
    More analyst ratings

    $RZLT
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by Rezolute Inc.

    SCHEDULE 13G - Rezolute, Inc. (0001509261) (Subject)

    1/30/26 2:43:53 PM ET
    $RZLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Rezolute Inc.

    SCHEDULE 13G/A - Rezolute, Inc. (0001509261) (Subject)

    1/8/26 9:09:46 AM ET
    $RZLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rezolute Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Rezolute, Inc. (0001509261) (Filer)

    1/7/26 6:10:48 AM ET
    $RZLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RZLT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Rezolute to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

    REDWOOD CITY, Calif., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (NASDAQ:RZLT) ("Rezolute" or the "Company"), a late-stage rare disease company focused on treating hypoglycemia caused by all forms of hyperinsulinism (HI), today announced that management will participate in the Guggenheim Emerging Outlook: Biotech Summit 2026, taking place February 11-12, 2026 in New York. Management will be participating in one-on-one investor meetings throughout the conference. Investors interested in scheduling a meeting with the Rezolute management team should contact their Guggenheim representative. About Rezolute, Inc. Rezolute is a late-stage rare disease company focused on treating hypoglyc

    2/4/26 7:00:00 AM ET
    $RZLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rezolute Provides Insights from its Phase 3 sunRIZE Study in Congenital Hyperinsulinism and Shares Findings from its Expanded Access Program in Tumor Hyperinsulinism

    Company believes that data from sunRIZE and the Expanded Access Program (EAP) provide evidence of activity of ersodetug in both indications Company plans to meet with FDA to align on path forward for congenital HI REDWOOD CITY, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (NASDAQ:RZLT) ("Rezolute" or the "Company"), a late-stage rare disease company focused on treating hypoglycemia caused by all forms of hyperinsulinism (HI), today shared observations from the Phase 3 sunRIZE study in patients with congenital HI and provided details on the treatment of tumor HI patients with ersodetug under the Company's EAP. Congenital HI While sunRIZE did not meet its primary (hypoglycemi

    1/7/26 7:00:00 AM ET
    $RZLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rezolute Announces Phase 3 sunRIZE Study Results in Congenital Hyperinsulinism

    Study did not meet the primary or key secondary endpoint  45% reduction in hypoglycemia events observed at top ersodetug dose (10 mg/kg) compared to 40% improvement in placebo arm Management to host conference call today at 8:30am ET REDWOOD CITY, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (NASDAQ:RZLT) ("Rezolute" or the "Company"), a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism, today announced topline results from its Phase 3 sunRIZE study evaluating ersodetug in patients with congenital hyperinsulinism (HI). The study did not meet its primary endpoint, which assessed change in the average weekly hypoglycemia events by self

    12/11/25 7:00:00 AM ET
    $RZLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RZLT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Hogenhuis Wladimir bought $9,548 worth of shares (5,650 units at $1.69), increasing direct ownership by 5% to 119,675 units (SEC Form 4)

    4 - Rezolute, Inc. (0001509261) (Issuer)

    12/17/25 4:14:55 PM ET
    $RZLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Medical Officer Roberts Brian Kenneth bought $47,600 worth of shares (28,000 units at $1.70), increasing direct ownership by 10% to 308,352 units (SEC Form 4)

    4 - Rezolute, Inc. (0001509261) (Issuer)

    12/17/25 4:13:53 PM ET
    $RZLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CFO Evans Daron bought $79,578 worth of shares (45,000 units at $1.77), increasing direct ownership by 11% to 415,900 units (SEC Form 4)

    4 - Rezolute, Inc. (0001509261) (Issuer)

    12/15/25 7:35:57 PM ET
    $RZLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RZLT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Rezolute downgraded by Craig Hallum with a new price target

    Craig Hallum downgraded Rezolute from Buy to Hold and set a new price target of $2.00

    12/11/25 3:51:30 PM ET
    $RZLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rezolute downgraded by Cantor Fitzgerald

    Cantor Fitzgerald downgraded Rezolute from Overweight to Neutral

    12/11/25 12:30:42 PM ET
    $RZLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rezolute downgraded by Wedbush with a new price target

    Wedbush downgraded Rezolute from Outperform to Neutral and set a new price target of $1.00

    12/11/25 10:36:07 AM ET
    $RZLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RZLT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Hogenhuis Wladimir bought $9,548 worth of shares (5,650 units at $1.69), increasing direct ownership by 5% to 119,675 units (SEC Form 4)

    4 - Rezolute, Inc. (0001509261) (Issuer)

    12/17/25 4:14:55 PM ET
    $RZLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Medical Officer Roberts Brian Kenneth bought $47,600 worth of shares (28,000 units at $1.70), increasing direct ownership by 10% to 308,352 units (SEC Form 4)

    4 - Rezolute, Inc. (0001509261) (Issuer)

    12/17/25 4:13:53 PM ET
    $RZLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CFO Evans Daron bought $79,578 worth of shares (45,000 units at $1.77), increasing direct ownership by 11% to 415,900 units (SEC Form 4)

    4 - Rezolute, Inc. (0001509261) (Issuer)

    12/15/25 7:35:57 PM ET
    $RZLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RZLT
    Leadership Updates

    Live Leadership Updates

    View All

    Rezolute Appoints Seasoned Commercial Executive Sunil Karnawat as Chief Commercial Officer

    REDWOOD CITY, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (NASDAQ:RZLT) ("Rezolute" or the "Company"), a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism (HI), today announced the appointment of Sunil Karnawat as Chief Commercial Officer, effective August 18, 2025. "We're thrilled to welcome Sunil to our leadership team at such a pivotal point as we advance ersodetug through Phase 3 studies for both congenital and tumor hyperinsulinism," said Nevan Charles Elam, Chief Executive Officer and Founder of Rezolute. "His proven track record of successfully bringing therapies to patients across multiple therapeutic areas, including four ultr

    8/20/25 7:30:00 AM ET
    $RZLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rezolute Reports Third Quarter Fiscal 2025 Financial Results and Provides Business Update

    sunRIZE enrollment on track including U.S. sites and expected to be completed in May 2025; topline data anticipated in December 2025 U.S. Food and Drug Administration (FDA) grants Breakthrough Therapy Designation to ersodetug for hypoglycemia due to tumor hyperinsulinism REDWOOD CITY, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (NASDAQ:RZLT) ("Rezolute" or the "Company"), a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism (HI), today reported financial results and provided a business update for the three months ended March 31, 2025. "The Phase 3 sunRIZE study in congenital HI is on track to complete enrollment this month and we are p

    5/13/25 4:05:00 PM ET
    $RZLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rezolute Announces Appointment of Rare Disease Commercial Leader Erik Harris to its Board of Directors

    REDWOOD CITY, Calif., March 26, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (NASDAQ:RZLT), a late-stage biopharmaceutical company dedicated to developing transformative therapies for rare diseases with serious unmet needs, announced the appointment of Erik Harris to its Board of Directors, effective immediately. Mr. Harris, who currently serves as Chief Commercial Officer and Executive Vice President at Ultragenyx, brings more than 20 years of biopharmaceutical expertise to Rezolute. "We are thrilled to welcome Erik to our board. He is a recognized rare disease commercial expert, and his insights will be invaluable as we advance our lead programs through clinical development and prepare for p

    3/26/25 7:30:00 AM ET
    $RZLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RZLT
    Financials

    Live finance-specific insights

    View All

    Rezolute Announces Phase 3 sunRIZE Study Results in Congenital Hyperinsulinism

    Study did not meet the primary or key secondary endpoint  45% reduction in hypoglycemia events observed at top ersodetug dose (10 mg/kg) compared to 40% improvement in placebo arm Management to host conference call today at 8:30am ET REDWOOD CITY, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (NASDAQ:RZLT) ("Rezolute" or the "Company"), a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism, today announced topline results from its Phase 3 sunRIZE study evaluating ersodetug in patients with congenital hyperinsulinism (HI). The study did not meet its primary endpoint, which assessed change in the average weekly hypoglycemia events by self

    12/11/25 7:00:00 AM ET
    $RZLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rezolute to Host Virtual Investor Event on Ersodetug Development Program

    REDWOOD CITY, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (NASDAQ:RZLT) ("Rezolute" or the "Company"), a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism, today announced that the company will host a virtual investor event via webcast on Monday, November 10, 2025, from 12:00 – 1:30 pm EST. The event will highlight the market opportunity and clinical development of ersodetug, which is currently being evaluated in two Phase 3 studies in congenital hyperinsulinism (HI) and tumor HI, respectively. During the event, Rezolute Chief Commercial Officer, Sunil Karnawat, will discuss the anticipated commercial opportunities for ersodetug as a p

    11/5/25 7:30:00 AM ET
    $RZLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rezolute Reports Second Quarter Fiscal 2024 Results and Provides Business Update

    Phase 3 clinical study of RZ358 underway in patients with congenital hyperinsulinism (cHI); topline results expected in mid-2025 Benefit shown in individual patient cases with RZ358 for tumor-associated hyperinsulinism (taHI) under Expanded Access Program (EAP); drives alignment with FDA on unmet need and potential to move into late-stage clinical development to further evaluate RZ358 in this population REDWOOD CITY, Calif., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Rezolute, Inc. (NASDAQ:RZLT) ("Rezolute" or the "Company"), a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for serious metabolic and rare diseases, today announced its financial re

    2/13/24 4:05:00 PM ET
    $RZLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RZLT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Rezolute Inc.

    SC 13G/A - Rezolute, Inc. (0001509261) (Subject)

    11/14/24 6:59:50 PM ET
    $RZLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Rezolute Inc.

    SC 13G/A - Rezolute, Inc. (0001509261) (Subject)

    11/14/24 10:04:23 AM ET
    $RZLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Rezolute Inc.

    SC 13G/A - Rezolute, Inc. (0001509261) (Subject)

    11/13/24 5:31:40 PM ET
    $RZLT
    Biotechnology: Pharmaceutical Preparations
    Health Care